Publications by authors named "Davide Pastorelli"

Claim this Profile
C
Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study).
Francesca Zacchi, Anna Sordo, Irene Torresan, Clara Lorenzi, Ester Tasselli, Davide Pastorelli

Front Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutritional Intervention for the Elderly during Chemotherapy: A Systematic Review.
Roberta Vella, Erica Pizzocaro, Elisa Bannone, Paola Gualtieri, Giulia Frank, Davide Pastorelli

Cancers (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABO-Incompatible Orthotopic Liver Transplant as a Rescue Strategy for Fulminant Hepatic Failure in a Recipient With Breast Cancer: Highlights on Transplant Management.
Alex Borin, Nicolò Caldonazzi, Albino Eccher, Luca Bortolasi, Claudio Bosio, Davide Pastorelli

Exp Clin Transplant· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Marco Maruzzo, Francesco Pierantoni, Alberto Bortolami, Dario Palleschi, Andrea Zivi, Davide Pastorelli

Target Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study.
Valentina Guarneri, Franco Bassan, Vittorina Zagonel, Michele Milella, Marta Zaninelli, Davide Pastorelli

Eur J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Filippo Pelizzaro, Ambra Sammarco, Vincenzo Dadduzio, Davide Pastorelli, Petros Giovanis

Dig Liver Dis· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Davide Pastorelli

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Ian Chau, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli

Br J Cancer· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.
Davide Pastorelli, Aline S C Fabricio, Petros Giovanis, Simona D'Ippolito, Pasquale Fiduccia

Pharmacol Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Marc Pracht, Vittorina Zagonel, Davide Pastorelli

Lancet Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Davide Pastorelli

Eur J Cancer· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib.
Petros Giovanis, Graziano Pianezze, Valter Vincenzi, Carla Manuppelli, Massimo Boaretto, Davide Pastorelli

Hepat Oncol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
Lorenza Rimassa, Maria Reig, Giovanni Abbadessa, Markus Peck-Radosavljevic, William Harris, Davide Pastorelli

World J Gastroenterol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nesidioblastosis coexisting with non-functioning islet cell tumour in an adult.
Valeria Valli, Stella Blandamura, Davide Pastorelli, Stefano Merigliano, Cosimo Sperti

Endokrynol Pol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic management of bone metastasis in prostate cancer: an update.
Fable Zustovich, Davide Pastorelli

Expert Rev Anticancer Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of psoriasis pustolosa palmaris induced by cetuximab.
Elena Marinello, Davide Pastorelli, Mauro Alaibac

BMJ Case Rep· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenteric-Portal Vein Resection during Pancreatectomy for Pancreatic Cancer.
Valentina Beltrame, Mario Gruppo, Sergio Pedrazzoli, Stefano Merigliano, Davide Pastorelli

Gastroenterol Res Pract· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Andrew X Zhu, Joon Oh Park, Baek-Yeol Ryoo, Chia-Jui Yen, Ronnie Poon, Davide Pastorelli

Lancet Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Lorenzo Antonuzzo, Elisa Giommoni, Davide Pastorelli, Tiziana Latiano, Ida Pavese

World J Gastroenterol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Francesco Panzuto, Maria Rinzivillo, Nicola Fazio, Filippo de Braud, Gabriele Luppi, Davide Pastorelli

Oncologist· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
Alessandro Cappetta, Laura Spano, Laura Evangelista, Stefania Zovato, Giuseppe Opocher, Davide Pastorelli

Anticancer Drugs· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Francesco Panzuto, Maria Rinzivillo, Nicola Fazio, Filippo de Braud, Gabriele Luppi, Davide Pastorelli

Oncologist· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature.
Valentina Beltrame, Mario Gruppo, Davide Pastorelli, Sara Pizzi, Stefano Merigliano

World J Surg Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Johanna C Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, Carlo Barone, Zev A Wainberg, Davide Pastorelli

Clin Colorectal Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience.
Davide Pastorelli, Maria Adelia Locatelli, Barbara Melotti, Carmela Pisano, Salvatore Turano

J Chemother· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis